ENBREL
LOE Approachingetanercept
BLASUBCUTANEOUSSYRINGEPriority Review
Approved
Nov 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
Priority Review
ENBREL (etanercept) is tumor necrosis factor receptor blocking activity [moa]. First approved in 1998.
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ENBREL (etanercept) is a TNF receptor fusion protein that blocks tumor necrosis factor signaling, a key driver of inflammatory diseases. It is administered subcutaneously via pre-filled syringe and is indicated for autoimmune conditions including rheumatoid arthritis and other TNF-mediated disorders. The drug works by binding soluble TNF and preventing its interaction with cell surface receptors.
$0.627BPart D
LOE ApproachingThe product is approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential team restructuring and focus shift toward lifecycle management and biosimilar defense strategies.
Mechanism of Action
Tumor Necrosis Factor Receptor Blocking Activity
Pharmacologic Class:
Tumor Necrosis Factor Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD
Started Sep 2025
122 enrolled
Graft vs Host Disease
A Study to Compare Efficacy, Pharmacokinetics, Safety and Immunogenicity of MB04 [Proposed Etanercept Biosimilar] to Enbrel® [EU-sourced] in Rheumatoid Arthritis
Started Oct 2024
501 enrolled
Rheumatoid Arthritis (RA)
A Study to Learn About the Adherence and Clinical Outcomes in Colombian Patients With an E-Device for Etanercept Administration in Rheumatoid Arthritis
Started Jun 2024
60 enrolled
Rheumatoid Arthritis
A Study of Nipocalimab With Co-administration of Etanercept or Hydroxychloroquine in Healthy Participants
Started Aug 2021
48 enrolled
Healthy
Etanercept Therapy for Nails Psoriasis Monitoring With Noninvasive Imaging
Started Aug 2021
10 enrolled
PsoriasisPsoriatic ArthritisPsoriatic Nail
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.